

Brad A Racette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6980620/publications.pdf>

Version: 2024-02-01

72
papers

3,382
citations

159585

30
h-index

149698

56
g-index

72
all docs

72
docs citations

72
times ranked

3906
citing authors

#	ARTICLE	IF	CITATIONS
1	Environmental manganese exposure and cognitive control in a South African population. <i>NeuroToxicology</i> , 2022, 89, 31-40.	3.0	6
2	Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial. <i>NeuroRehabilitation</i> , 2022, 50, 33-46.	1.3	6
3	Solvent exposed occupations and risk of Parkinson disease in Finland. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 4, 100092.	0.9	5
4	Severity of parkinsonism associated with environmental manganese exposure. <i>Environmental Health</i> , 2021, 20, 27.	4.0	23
5	Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese-Exposed Workers. <i>Toxicological Sciences</i> , 2021, 182, 132-141.	3.1	3
6	A Rapid Motor Task-Based Screening Tool for Parkinsonism in Community-Based Studies. <i>Frontiers in Neurology</i> , 2021, 12, 653066.	2.4	1
7	Depression and anxiety in a manganese-exposed community. <i>NeuroToxicology</i> , 2021, 85, 222-233.	3.0	14
8	A comparison of prediction approaches for identifying prodromal Parkinson disease. <i>PLoS ONE</i> , 2021, 16, e0256592.	2.5	5
9	Manganese exposure, parkinsonian signs, and quality of life in South African mine workers. <i>American Journal of Industrial Medicine</i> , 2020, 63, 36-43.	2.1	30
10	[11C]dihydrotetrabenazine Positron Emission Tomography in Manganese-Exposed Workers. <i>Journal of Occupational and Environmental Medicine</i> , 2020, 62, 788-794.	1.7	3
11	Validation of Parkinson's Disease-Related Questionnaires in South Africa. <i>Parkinson's Disease</i> , 2020, 2020, 1-9.	1.1	5
12	Fractures in the prodromal period of Parkinson disease. <i>Neurology</i> , 2020, 94, e2448-e2456.	1.1	8
13	Well Water and Parkinson's Disease in Medicare Beneficiaries: A Nationwide Case-Control Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 693-705.	2.8	9
14	Validation of a Parkinson Disease Predictive Model in a Population-Based Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-7.	1.1	5
15	Herpesvirus Infections and Risk of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2020, 20, 97-103.	1.4	12
16	Transplant and risk of Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 149-155.	2.2	5
17	MRI Signal Intensity and Parkinsonism in Manganese-Exposed Workers. <i>Journal of Occupational and Environmental Medicine</i> , 2019, 61, 641-645.	1.7	26
18	The reproducibility of urinary ions in manganese exposed workers. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 51, 204-211.	3.0	5

#	ARTICLE	IF	CITATIONS
19	Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 23-28.	2.2	61
20	A screening tool to detect clinical manganese neurotoxicity. <i>NeuroToxicology</i> , 2018, 64, 12-18.	3.0	3
21	[18 F]FDOPA positron emission tomography in manganese-exposed workers. <i>NeuroToxicology</i> , 2018, 64, 43-49.	3.0	23
22	α2-adrenoreceptor medications and risk of Parkinson disease. <i>Annals of Neurology</i> , 2018, 84, 683-693.	5.3	59
23	Immunosuppressants and risk of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 870-875.	3.7	61
24	Inflammatory bowel disease and risk of Parkinson's disease in medicare beneficiaries. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 77.	2.2	8
25	Author response: A predictive model to identify Parkinson disease from administrative claims data. <i>Neurology</i> , 2018, 91, 104-104.	1.1	0
26	Use of medical care biases associations between Parkinson disease and other medical conditions. <i>Neurology</i> , 2018, 90, e2155-e2165.	1.1	17
27	Selective D2 receptor PET in manganese-exposed workers. <i>Neurology</i> , 2018, 91, e1022-e1030.	1.1	27
28	Cognitive control dysfunction in workers exposed to manganese-containing welding fume. <i>American Journal of Industrial Medicine</i> , 2017, 60, 181-188.	2.1	18
29	Parkinsonism Signs and Symptoms in Agricultural Pesticide Handlers in Washington State. <i>Journal of Agromedicine</i> , 2017, 22, 215-221.	1.5	4
30	Dose-dependent progression of parkinsonism in manganese-exposed welders. <i>Neurology</i> , 2017, 88, 344-351.	1.1	92
31	Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare data. <i>Annals of Neurology</i> , 2017, 82, 744-754.	5.3	39
32	A predictive model to identify Parkinson disease from administrative claims data. <i>Neurology</i> , 2017, 89, 1448-1456.	1.1	47
33	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 40.	7.4	327
34	Parkinson disease and cognitive impairment. <i>Neurology: Clinical Practice</i> , 2016, 6, 452-458.	1.6	34
35	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). <i>JAMA Neurology</i> , 2016, 73, 102.	9.0	38
36	Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. <i>Neurobiology of Aging</i> , 2016, 37, 209.e1-209.e7.	3.1	106

#	ARTICLE	IF	CITATIONS
37	Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurology</i> , 2015, 14, 710-719.	10.2	243
38	Ex vivo magnetic resonance imaging in South African manganese mine workers. <i>NeuroToxicology</i> , 2015, 49, 8-14.	3.0	12
39	Inducible nitric oxide synthase gene methylation and parkinsonism in manganese-exposed welders. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 355-360.	2.2	28
40	Physician response to a medication alert system in inpatients with levodopa-treated diseases. <i>Neurology</i> , 2015, 85, 420-424.	1.1	4
41	Time to change the blind men and the elephant approach to Parkinson disease?. <i>Neurology</i> , 2015, 85, 190-196.	1.1	24
42	Neuromythology of Manganism. <i>Current Epidemiology Reports</i> , 2015, 2, 143-148.	2.4	41
43	Nursing home and end-of-life care in Parkinson disease. <i>Neurology</i> , 2015, 85, 413-419.	1.1	87
44	Relative Mortality in U.S. Medicare Beneficiaries with Parkinson Disease and Hip and Pelvic Fractures. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, e27.	3.0	36
45	Screening for early detection of parkinsonism using a self-administered questionnaire: A cross-sectional epidemiologic study. <i>NeuroToxicology</i> , 2014, 45, 232-237.	3.0	3
46	Quantitative neuropathology associated with chronic manganese exposure in South African mine workers. <i>NeuroToxicology</i> , 2014, 45, 260-266.	3.0	38
47	Manganism in the 21st century: The Hanninen lecture. <i>NeuroToxicology</i> , 2014, 45, 201-207.	3.0	64
48	Blood Manganese as an Exposure Biomarker: State of the Evidence. <i>Journal of Occupational and Environmental Hygiene</i> , 2014, 11, 210-217.	1.0	64
49	A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. <i>F1000Research</i> , 2013, 2, 150.	1.6	28
50	Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. <i>Neurology</i> , 2012, 79, 1774-1780.	1.1	86
51	Predictors of Survival in Patients With Parkinson Disease. <i>Archives of Neurology</i> , 2012, 69, 601.	4.5	130
52	Pathophysiology of manganese-associated neurotoxicity. <i>NeuroToxicology</i> , 2012, 33, 881-886.	3.0	115
53	Increased risk of parkinsonism associated with welding exposure. <i>NeuroToxicology</i> , 2012, 33, 1356-1361.	3.0	132
54	Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. <i>Occupational and Environmental Medicine</i> , 2012, 69, 437-443.	2.8	98

#	ARTICLE	IF	CITATIONS
55	Estimation of Particulate Mass and Manganese Exposure Levels among Welders. <i>Annals of Occupational Hygiene</i> , 2011, 55, 113-25.	1.9	39
56	Effects of parkinsonism on health status in welding exposed workers. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 672-676.	2.2	20
57	Metal Emissions and Urban Incident Parkinson Disease: A Community Health Study of Medicare Beneficiaries by Using Geographic Information Systems. <i>American Journal of Epidemiology</i> , 2010, 172, 1357-1363.	3.4	130
58	Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. <i>Neuroepidemiology</i> , 2010, 34, 143-151.	2.3	330
59	Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 197-201.	2.2	20
60	A Population-Based Study of Parkinsonism in an Amish Community. <i>Neuroepidemiology</i> , 2009, 33, 225-230.	2.3	24
61	Validity and Reliability of an Occupational Exposure Questionnaire for Parkinsonism in Welders. <i>Journal of Occupational and Environmental Hygiene</i> , 2009, 6, 324-331.	1.0	28
62	A rapid method for mass screening for parkinsonism. <i>NeuroToxicology</i> , 2006, 27, 357-361.	3.0	14
63	[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 245-249.	1.7	11
64	The impact of litigation on neurologic research. <i>Neurology</i> , 2006, 67, 2124-2128.	1.1	7
65	[18F]FDOPA PET and clinical features in parkinsonism due to manganism. <i>Movement Disorders</i> , 2005, 20, 492-496.	3.9	106
66	Botulinum toxin B reduces sialorrhea in parkinsonism. <i>Movement Disorders</i> , 2003, 18, 1059-1061.	3.9	60
67	Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2002, 14, 438-442.	1.8	37
68	Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). <i>Movement Disorders</i> , 2002, 17, 1098-1100.	3.9	12
69	Thalamic stimulation for primary writing tremor. <i>Journal of Neurology</i> , 2001, 248, 380-382.	3.6	41
70	Late-Onset neurodegeneration with brain iron accumulation type 1: Expanding the clinical spectrum. <i>Movement Disorders</i> , 2001, 16, 1148-1152.	3.9	18
71	Chorea and jaw-opening dystonia as a manifestation of Neurobehcet's syndrome. <i>Movement Disorders</i> , 2000, 15, 741-744.	3.9	18
72	Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. <i>American Journal of Medical Genetics Part A</i> , 1999, 88, 539-543.	2.4	99